Trials / Completed
CompletedNCT00608153
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,773 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.
Conditions
Timeline
- Start date
- 2007-01-01
- Completion
- 2007-09-01
- First posted
- 2008-02-06
- Last updated
- 2008-02-06
Source: ClinicalTrials.gov record NCT00608153. Inclusion in this directory is not an endorsement.